Lupus & antiphospholipid syndrome
Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study
Authors' conclusion
Because clinical inertia can drive damage accrual and QoL deterioration, avoiding clinical inertia is a therapeutic priority.
Study context
- Population
- Patients with SLE with active disease 1 year before baseline (SLE Disease Activity Index score >4 or active gastrointestinal lesions or haemolytic anaemia), multicentre LUNA cohort, Japan
- Participants
- 365 patients
- Exposure
- Non-intensification vs intensification of treatment; clinical inertia vs non-clinical inertia
- Non-intensificationn = 247
- Intensificationn = 118reference
- Clinical inertian = 116
- Non-clinical inertian = 249reference
- Outcome
- Outcomes and predictors of non-intensification and clinical inertia
Methodological detailsmulticentre, LUNA cohort
- Multicentre
- LUNA cohort
Main finding
As reported in the abstract
- Non-intensification associated with larger increases in GC-related damage
- Clinical inertia linked to greater increases in overall and GC-related damage
- Non-intensification and clinical inertia correlated with a tendency towards reduced quality of life (QoL) across several domains
- HCQ use and fewer concomitant immunosuppressants predicted non-intensification
- Female sex and greater damage accrual predicted clinical inertia
- Older age showed similar but non-significant trends for both outcomes
Observational data: associations, not effects.
Original publication
Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study. Rheumatology (Oxford). Published 22 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →